UsaBra Logo

Entre em contato conosco para maiores informações sobre como importar no nosso WhatsApp.

Orlando / Florida
1-407-990-2876
contato@usabrashopper.com

UsaBra Shopper

Zoll Plus Agreement

June 11, 2019 – CHELMSFORD, MASS.- ZOLL® Medical Corporation, an Asahi Kasei Group that manufactures medical devices and related software solutions, announced today that it has signed a final agreement to purchase Cardiac Science Corporation (CSC), a leading provider of external automated defibrillators (EDAs), related services and accessories. CSC is a holding company of Aurora Resurgence, a private equity firm based in Los Angeles. As part of the agreement, ZOLL will purchase Cardiac Science`s product portfolio and pipeline, as well as its facilities in the United States and Europe. Other terms of the agreement will not be disclosed. The transaction is subject to authorization for cartels and abuse of dominance and other normal closing conditions. Until the closure, the companies will work independently. The transaction is subject to authority approval and other normal closing conditions. Other terms of the agreement are not disclosed at this time. “We are delighted that ZOLL is the right company to defend our high-quality portfolio and use its presence and vision to expand access and use applications in communities around the world,” said Dev Kurdikar, President and CEO of Cardiac Science. “The agreement reflects ZOLL`s appreciation for the value of our technology, and I am confident that customers will benefit from the growing resources and reach of our combined portfolios.” ZOLL Medical Corporation, a company of the Asahi Kasei Group, develops and distributes medical equipment and software solutions that contribute to emergency supply and save lives while improving clinical and operational efficiency.

With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management and ventilation, ZOLL offers a comprehensive set of technologies that help physicians, EMS professionals and firefighters and treat victims in need of acute resuscitation and critical care. For more information, see www.zoll.com. JUNE 11, 2019, DEERFIELD, Wisc. – Cardiac Science Corporation (CSC), a leading provider of automated external defibrillators (AEDs), related services and accessories, announced today that it has entered into a final agreement to be acquired by ZOLL® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions. CSC is a holding company of Aurora Resurgence, a private equity firm based in Los Angeles. . The three categories proposed in this portfolio are: Cardiac Science is introducing new solutions this year that improve the usability and performance of AED systems and strengthen their strong portfolio and quality balance sheet. . Cintas offers you two first-class AED options when setting up your AED program: the ReviveR® View AED and the ZOLL® AED Plus®.

The Philips HeartStart OnSite is lightweight, but powerful and easy to use. Asahi Kasei Group is a diversified group of companies, managed by the holding company Asahi Kasei Corp., which operates in the areas of equipment, budget and healthcare. Health care includes acute critical care devices and systems, dialysis, therapeutic apheresis, transfusion and biotherapy, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees worldwide, the Asahi Kasei Group handles customers in more than 100 countries. For more information, see www.asahi-kasei.co.jp/asahi/en/. Preventive maintenance is available at all times. ZOLL offers preventive maintenance contracts, both annual and semi-annual. All preventative maintenance programs include the use of a service loan. On-site prevention maintenance is available at many sites. The Master Agreements in this portfolio offer fixed prices for up to three categories of AED units, DEA defibrillators and associated accessories. “Joining ZOLL is a good opportunity for our company, our employees and our customers,” said Dev Kurdikar, President and CEO of Cardiac Science.